Richardson P J, Meany T B, Johnston G D, Kondowe G, Grimmer S F, Breckenridge A M
Department of Cardiology, Kings College Hospital, London, England.
J Cardiovasc Pharmacol. 1987;10 Suppl 10:S96-8.
Lisinopril, a long-acting angiotensin converting enzyme inhibitor, and the calcium channel blocker nifedipine in its retard formulation, were compared as monotherapy in a group of 45 patients with essential hypertension. Lisinopril in single daily doses (range 20-80 mg, median dose 40 mg) and nifedipine retard in twice daily doses (total daily dose range 40-80 mg, median dose 60 mg) were equally effective in controlling hypertension. The lisinopril group (n = 30), at baseline supine blood pressure 178/109 +/- 23/9 mm Hg (mean +/- 1 SD), after 12 weeks' therapy measured 148/88 +/- 27/14 mm Hg; the nifedipine group (n = 15), at baseline 185/110 +/- 23/11 mm Hg, after 12 weeks' therapy measured 151/89 +/- 14/10 mm Hg. The number of patients who experienced clinical adverse effects was significantly greater in the nifedipine group: 8 of 15 (53%) compared to 4 of 30 (13%) in the lisinopril group. The commonest adverse effects of patients on nifedipine were swollen ankles, flushing, and headache. Two patients on nifedipine were withdrawn from the study because of their adverse experiences. Of the patients on lisinopril there were single reports of flushing, ankle swelling, tiredness, and chest pain. No patient withdrew from lisinopril because of an adverse experience. No adverse laboratory experiences were recorded in either group. In conclusion, lisinopril and nifedipine retard were equally effective in controlling essential hypertension. Lisinopril was, however, better tolerated during this study.
赖诺普利是一种长效血管紧张素转换酶抑制剂，将其与缓释制剂的钙通道阻滞剂硝苯地平作为单一疗法，在45例原发性高血压患者中进行了比较。赖诺普利每日单次给药（剂量范围20 - 80毫克，中位剂量40毫克）和硝苯地平缓释片每日两次给药（每日总剂量范围40 - 80毫克，中位剂量60毫克）在控制高血压方面同样有效。赖诺普利组（n = 30），基线仰卧位血压为178/109±23/9毫米汞柱（平均值±1标准差），经过12周治疗后为148/88±27/14毫米汞柱；硝苯地平组（n = 15），基线血压为185/110±23/11毫米汞柱，经过12周治疗后为151/89±14/10毫米汞柱。硝苯地平组出现临床不良反应的患者数量明显更多：15例中有8例（53%），而赖诺普利组30例中有4例（13%）。服用硝苯地平的患者最常见的不良反应是脚踝肿胀、面部潮红和头痛。两名服用硝苯地平的患者因不良反应退出研究。服用赖诺普利的患者有单次出现面部潮红、脚踝肿胀、疲劳和胸痛的报告。没有患者因不良反应退出赖诺普利治疗组。两组均未记录到不良实验室检查结果。总之，赖诺普利和硝苯地平缓释片在控制原发性高血压方面同样有效。然而，在本研究中赖诺普利的耐受性更好。
